PCTAIRE-3 Activators encompass a range of chemical compounds that, through various signaling pathways, indirectly enhance the functional activity of PCTAIRE-3. Compounds such as Forskolin and Dibutyryl-cAMP elevate intracellular cAMP, thereby activating PKA, which is known to phosphorylate target proteins, potentially including PCTAIRE-3, thereby enhancing its kinase activity in processes like cell cycle regulation. Similarly, Isoproterenol, a beta-adrenergic agonist, also raises cAMP levels, indirectly promoting PCTAIRE-3 activation. Retinoic Acid modulates cellular differentiation, which could implicate PCTAIRE-3 in the enhanced signaling required for these processes, especially in neuronal cells. Epigallocatechin Gallate (EGCG) and Staurosporine, both kinase inhibitors, could selectively inhibit kinases that normally suppress PCTAIRE-3, allowing for an indirect increase in its activity. Sphingosine-1-phosphate, while primarily involved in signal transduction, could intersect with pathways that engage PCTAIRE-3, enhancing its activity in cellular signaling.
Furthermore, compounds like LY294002, a PI3K inhibitor, and PD98059, an MEK inhibitor, may shift cellular signaling dynamics, leading to an indirect upregulation of PCTAIRE-3 activity. These inhibitors could reduce the activity of competing pathways or release PCTAIRE-3 from negative regulation. A23187 (Calcimycin) increases intracellular calcium, potentially affecting calcium-dependent protein kinases and phosphatases that modulate PCTAIRE-3's role, leading to enhanced activity. IBMX, by inhibiting phosphodiesterases, increases cAMP levels, which may further contribute to PKA-mediated activation of PCTAIRE-3. Lastly, Zoledronic Acid, by interfering with the mevalonate pathway, could alter the function or localization of proteins interacting with PCTAIRE-3, thereby enhancing its kinase activity. Collectively, these activators, through their targeted biochemical mechanisms, facilitate the enhancement of PCTAIRE-3 mediated functions in various cellular contexts.
SEE ALSO...
Items 11 to 17 of 17 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, potentially affecting calcium-dependent protein kinases and phosphatases that modulate PCTAIRE-3 activity and its role in cellular functions. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, elevates cAMP levels and thereby activates PKA, which may enhance PCTAIRE-3 by phosphorylation or changes in interaction with binding partners. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a phosphodiesterase 3 inhibitor that elevates cAMP levels, which can enhance PKA activity. PKA, in turn, may phosphorylate and activate PCTAIRE-3. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, leading to increased cAMP and PKA activation. PKA could then phosphorylate PCTAIRE-3, enhancing its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, an MEK inhibitor, could modulate MAPK/ERK pathway activity, potentially leading to altered PCTAIRE-3 activity as a result of changes in the signaling network. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor that also increases cAMP levels, potentially leading to PKA-mediated phosphorylation and activation of PCTAIRE-3. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid interferes with mevalonate pathway, potentially altering prenylation and thus activity or localization of proteins that interact with PCTAIRE-3, leading to its enhanced activity. | ||||||